Area of research
Hematology · Genetics
Research interest
Research focused on Myeloid leukemia and Venetoclax, with related work in Arsenic trioxide, Mutation, IDH2. Notable publications include 'MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide', 'HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study', and 'Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia'.
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study
Next generation sequencing reveals the mutation landscape of Chinese MDS patients and the association between mutations and AML transformations
CACA guidelines for holistic integrative management of adult acute myeloid leukemia
A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study
Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia
Mitoxantrone Hydrochloride Liposome Containing Regimen in Patients with Adult Acute Lymphoblastic Leukemia: A Multicenter, Retrospective, Real-World Study
Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide